Editorial policy
Conflict of interest policy
Metabolic Peptides accepts a sponsored advertising partnership from PeptideBarn.co.uk, a UK research-peptide reference supplier, disclosed on every ad unit. Sponsorship does not influence editorial content. No manufacturer, compounding-pharmacy or online-pharmacy relationships.
Manufacturer independence
No member of the editorial team or the scientific review panel has a commercial relationship with any manufacturer of incretin medicines, growth-hormone-axis peptides or any compound discussed on this site — including Eli Lilly, Novo Nordisk, Pfizer, Boehringer Ingelheim, Amgen, Zealand Pharma, Hanmi, Theratechnologies, AstraZeneca and others active in this space.
Sponsored advertising partnership — PeptideBarn.co.uk
Disclosure. The site accepts a sponsored advertising partnership from PeptideBarn.co.uk, a UK-based research-peptide reference supplier. PeptideBarn appears in clearly labelled ad units across the site — a hero banner on the homepage, a footer partner column, inline sidebar cards on peptide profile pages (rendered via the site's SponsoredPartnerCard component), and a dedicated CTA on brand landing pages.
Compliance. Every sponsored placement carries the visible "Sponsored" label BEFORE the ad content, per UK ASA / CAP Code disclosure requirements. All outbound links to peptidebarn.co.uk use rel="sponsored noopener" and target="_blank", in line with Google Webmaster paid-link guidance.
Editorial independence. The sponsored partnership does not influence editorial content. Trial coverage, molecule profile selection, safety signal tracking, regulatory framing, evidence grading and the choice of what to include in comparison pages are determined by the editorial team under our editorial standards and source selection policy. PeptideBarn has no editorial approval rights and does not review content pre-publication.
Boundary. PeptideBarn supplies research-grade reference peptides for laboratory use — not licensed medicines. The site continues to distinguish UK-licensed prescription-only medicines (Mounjaro, Wegovy, Ozempic, Saxenda, Rybelsus, Victoza, Trulicity) from investigational and research-only compounds, and the sponsored placement does not present research-grade material as a substitute for licensed medicine.
Sister site — PeptideAuthority.co.uk
The site cross-links to PeptideAuthority.co.uk as a sister editorial resource. This is a non-monetary cross-reference between two editorial sites in the same peptide-research space.
No manufacturer relationships
We do not have paid or unpaid commercial relationships with any manufacturer of incretin medicines, with any compounding pharmacy, or with any online-pharmacy / telehealth service. Manufacturer press releases are cited as such where they are the best available source for a topline result, with that fact flagged.
No advertising of prescription-only medicines to the public
Public advertising of POMs is restricted in the UK. Our editorial covers UK-licensed medicines (Mounjaro, Wegovy, Ozempic, Saxenda, Rybelsus, Victoza, Trulicity) only as educational, journalistic and trial-evidence reference. We do not run promotional language, before / after imagery, influencer claims, or calls to obtain the medicine from any specific source — see the how we classify these medicines for how we define prescription-only, investigational and research-only categories, and the rules that apply to each.
What this site does receive
We accept no commercial payments related to the metabolic peptide editorial itself. The site is funded by its operator and any non-conflicting infrastructure costs (hosting, domain). Where any non-conflicting commercial relationship is in place — for example, basic email or hosting services — it does not influence editorial content.
How to flag a perceived conflict
If you believe a page reads as if a conflict of interest is influencing its framing, report it via the contact page. Concerns are treated as a corrections priority and reviewed by an editor who was not involved in writing the page.